Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.

Pfeuffer S, Rolfes L, Wirth T, Steffen F, Pawlitzki M, Schulte-Mecklenbeck A, Gross CC, Brand M, Bittner S, Ruck T, Klotz L, Wiendl H, Meuth SG

Research article (journal) | Peer reviewed

Abstract

In this observational study, patients with steroid-refractory acute multiple sclerosis relapses receiving either six courses of tryptophan-immunoadsorption or double-dose methylprednisolone therapy were analysed. Outcomes were evaluated at discharge and three months later. Immune profiling of blood lymphocytes and proteomic analysis were performed by multi-parameter flow cytometry and Olink analysis, respectively (NCT04450030).

Details about the publication

JournalJournal of Neuroinflammation
Volume19
Issue1
Page range220-220
StatusPublished
Release year2022 (07/09/2022)
Language in which the publication is writtenEnglish
KeywordsHumans; Methylprednisolone; Multiple Sclerosis; Prospective Studies; Proteomics; Quality of Life; Recurrence

Authors from the University of Münster

Groß, Catharina
Klotz, Luisa Hildegard
Meuth, Sven
Schulte-Mecklenbeck, Andreas
Wiendl, Heinz Siegfried
Wirth, Timo